Eledon Pharmaceuticals Inc ELDN

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Eledon Pharmaceuticals Inc (ELDN) vs. Its Peers: A Comparison

4d ago, source: newsheater

During the last 5 trading sessions, ELDN rose by +19.88%, which changed the moving average for the period of 200-days by +42.14% in comparison to the 20-day moving average, which settled at $1.8290.

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

1mon ago, source: Nasdaq

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company ...

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

25d ago, source: Business Insider

March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2023 operating and financial results and reviewed rece ...

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

28d ago, source: Business Insider

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12 th participant on March 23, 2024, in the ...

Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

25d ago, source: Finanznachrichten

March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today reported its fourth quarter and full year 2023 operating and financial results and reviewed recent ...

Eledon Pharmaceuticals Inc ELDN

29d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eledon Pharmaceuticals Inc.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Eledon Pharmaceuticals Inc (ELDN)

26d ago, source: Investing

Eledon Pharmaceuticals, Inc. (“Eledon”) (ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key ...